Table 3.
Clinical correlates of a) baseline abnormal PWV (≥10 m/s); b) baseline PWV and c) 12-month PWV in the entire study population
| Unadjusted OR (95% CI) | p | Adjusted OR (95% CI)a | p | |
| a) Abnormal PWV (≥10 m/s) at baseline | ||||
| Age (year) | 1.12 (1.05–1.19) | 0.001 | 1.14 (1.04–1.25) | 0.004 |
| Diabetes | 3.75 (1.33–10.56) | 0.01 | 9.73 (1.37–69.0) | 0.02 |
| Log FGF23 (pg/mL) | 1.67 (1.14–2.43) | 0.007 | 2.95 (1.04–8.34) | 0.04 |
| Log PTH (pg/mL) | 1.79 (1.03–3.08) | 0.04 | 3.78 (1.31–10.9) | 0.01 |
| eGFR(ml/min/1.73m2) | 0.99 (0.97–1.00) | 0.07 | 1.08 (1.03–1.15) | 0.004 |
| Unadjusted Coefficient (95% CI) | p | Adjusted Coefficient (95% CI)a | p | |
| b) Baseline PWV | ||||
| Age (year) | 0.02 (0.01–0.02) | <0.001 | 0.01 (0.01–0.02) | <0.001 |
| Hypertension | 0.25 (0.14–0.37) | <0.001 | 0.24 (0.16–0.37) | <0.001 |
| eGFR(ml/min/1.73m2) | −0.002 (−0.003–0.0004) | 0.06 | 0.006 (0.003–0.008) | <0.001 |
| Log PTH (pg/mL) | 0.08 (0.02–0.2) | 0.02 | 0.13 (0.06–0.20) | <0.001 |
| Log FGF23 (pg/mL) | 0.06 (0.01–0.10) | 0.01 | 0.05 (−0.003–0.11) | 0.06 |
| c) 12-month PWV | ||||
| Baseline PWV (m/s) | 0.73 (0.56–0.90) | <0.001 | 0.49 (0.31–0.68) | <0.001 |
| Diabetes | 0.18 (0.08–0.29) | 0.001 | 0.16 (0.06–0.26) | 0.002 |
| uPCR (mg/mmol) | 0.0007 (0.0003–0.001) | 0.002 | 0.0006 (0.0001–0.001) | 0.008 |
| Log FGF23 (pg/mL) | 0.06 (0.03–0.10) | 0.001 | 0.04 (0.005–0.07) | 0.03 |
aAdjusted for age, diabetes, hypertension, eGFR, uPCR, corrected calcium, phosphate, PTH and FGF23
Abbreviations: CI confidence interval, eGFR estimated glomerular filtration rate, FGF23 fibroblast growth factor 23, OR odds ratio, PTH parathyroid hormone level, PWV pulse wave velocity, UPCR urinary protein-to-creatinine ratio